DACOGEN® (decitabine) for Injection is a therapy approved to treat myelodysplastic
syndromes (MDS). It can help treat the disease and improve your MDS symptoms. Even
if you have already received other treatment for MDS, you can still be treated with
DACOGEN.
DACOGEN.com is your resource for MDS information and the treatment with DACOGEN.
Learn how DACOGEN helps relieve
MDS symptoms
and
works to change
the course of the disease.
DACOGEN is indicated for treatment of patients with myelodysplastic syndromes (MDS),
including previously treated and untreated, de novo, and secondary MDS of all FAB
subtypes (RA, RARS, RAEB, RAEB-t, CMML) and Intermediate-1, Intermediate-2, and
High-Risk IPSS groups.
DACOGEN may cause fetal harm when administered to a pregnant woman. Women of childbearing
potential should be advised to avoid becoming pregnant while using DACOGEN. Men
should be advised not to father a child while receiving treatment with DACOGEN,
and for 2 months afterwards. The most commonly occurring adverse reactions include
neutropenia, thrombocytopenia, anemia, fatigue, pyrexia, nausea, cough, petechiae,
constipation, diarrhea, and hyperglycemia.
DACOGEN is available by prescription only. Please see the important product information
for DACOGEN for more information. This site does not contain everything that is
known about DACOGEN. If you would like to know more, talk to your healthcare professional.